Unity Biotechnology, Inc. (UBX)
Largest Insider Buys in Sector
UBX Stock Price History Chart
UBX Stock Performance
About Unity Biotechnology, Inc.
Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase II clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of age-related eye …
Insider Activity of Unity Biotechnology, Inc.
Over the last 12 months, insiders at Unity Biotechnology, Inc. have bought $0 and sold $8,680 worth of Unity Biotechnology, Inc. stock.
On average, over the past 5 years, insiders at Unity Biotechnology, Inc. have bought $56,956 and sold $2.25M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 6,400 shares for transaction amount of $56,956 was made by David Nathaniel E (President) on 2020‑06‑05.
List of Insider Buy and Sell Transactions, Unity Biotechnology, Inc.
| 2024-11-04 | Sale | Chief Executive Officer | 432 0.0026% | $1.29 | $557 | -5.16% | ||
| 2024-11-04 | Sale | CFO & Head of Corp. Dev. | 136 0.0008% | $1.29 | $175 | -5.16% | ||
| 2024-11-04 | Sale | Chief Legal Officer | 149 0.0009% | $1.29 | $192 | -5.16% | ||
| 2024-08-02 | Sale | Chief Executive Officer | 604 0.0038% | $1.53 | $924 | -1.37% | ||
| 2024-08-02 | Sale | CFO & Head of Corp. Dev. | 139 0.0009% | $1.53 | $213 | -1.37% | ||
| 2024-08-02 | Sale | Chief Legal Officer | 154 0.001% | $1.53 | $236 | -1.37% | ||
| 2024-06-25 | Sale | Chief Executive Officer | 1,214 0.0072% | $1.40 | $1,700 | +2.13% | ||
| 2024-06-25 | Sale | CFO & Head of Corp. Dev. | 324 0.0019% | $1.40 | $454 | +2.13% | ||
| 2024-06-25 | Sale | Chief Legal Officer | 78 0.0005% | $1.40 | $109 | +2.13% | ||
| 2024-05-02 | Sale | Chief Executive Officer | 603 0.0034% | $1.55 | $935 | -10.43% | ||
| 2024-02-02 | Sale | Chief Executive Officer | 680 0.0041% | $1.71 | $1,163 | -14.20% | ||
| 2024-01-30 | Sale | Chief Executive Officer | 1,183 0.0072% | $1.71 | $2,023 | -11.18% | ||
| 2023-11-02 | Sale | Chief Executive Officer | 589 0.0037% | $1.83 | $1,078 | -20.71% | ||
| 2023-10-30 | Sale | Chief Executive Officer | 1,024 0.0069% | $1.90 | $1,946 | -17.71% | ||
| 2023-09-14 | Sale | Chief Executive Officer | 1,246 0.0085% | $2.47 | $3,078 | -32.79% | ||
| 2023-08-02 | Sale | Chief Executive Officer | 581 0.0043% | $2.94 | $1,708 | -36.84% | ||
| 2023-07-31 | Sale | Chief Executive Officer | 1,020 0.0075% | $2.86 | $2,917 | -36.82% | ||
| 2023-06-26 | Sale | Chief Executive Officer | 1,177 0.0085% | $3.20 | $3,766 | -41.48% | ||
| 2023-06-14 | Sale | Chief Executive Officer | 1,212 0.0087% | $3.39 | $4,109 | -44.71% | ||
| 2023-05-02 | Sale | Chief Executive Officer | 588 0.004% | $2.17 | $1,276 | -13.06% |
Institutional Investor Ownership
| Arch Venture Management Llc | $1.65M | 5.99 | 1M | 0% | +$0 | 0.08 | |
| Alyeska Investment Group L P | $1.51M | 5.48 | 920,013 | -11.65% | -$198,961.48 | 0.01 | |
| The Vanguard Group | $914,059.00 | 3.32 | 557,353 | -0.76% | -$6,968.36 | <0.0001 | |
| Geode Capital Management | $220,035.00 | 0.8 | 134,133 | +1.78% | +$3,856.64 | <0.0001 | |
| Mayo Clinic | $203,493.00 | 0.74 | 124,081 | 0% | +$0 | 0.02 |